Frontiers | Anakinra Therapy for Non-cancer Inflammatory Diseases
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study - The Lancet Rheumatology
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy - Transplantation and Cellular Therapy, Official Publication of the American Society for ...
Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance - Sofia Ajeganova, Ann De Becker, Rik Schots, 2020
PulmCrit – High-dose anakinra for COVID-19: The anti-inflammatory trials begin
Kineret Subcutaneous: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD
KINERET Dosage & Rx Info | Uses, Side Effects
Arthritis News: Study Finds No Treatment Benefit of Intra-Articular Anakinra in Knee Osteoarthritis
Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study | Clinical Rheumatology
Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes | BMC Pharmacology and Toxicology | Full Text
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS) | Journal for ImmunoTherapy of Cancer
The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis - Bami - 2020 - Pediatric Blood & Cancer - Wiley Online Library
Kineret (Anakinra): Uses, Dosage, Side Effects, Interactions, Warning
KINERET® (anakinra) Official Website | Using KINERET for NOMID
Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study | Clinical Rheumatology
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry | The Journal of Rheumatology
Clinical Commissioning Policy: Anakinra for Haemophagocytic Lymphohistiocytosis (HLH) for adults and children in all ages [21070
Anakinra reduces ventilation need, mortality in COVID-19
Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness - International Journal of Infectious Diseases
Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis | Annals of the Rheumatic Diseases
Frontiers | Anakinra Pilot – a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants
Frontiers | Anakinra in Paediatric Rheumatology and Periodic Fever Clinics: Is the Higher Dose Safe?
Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome - The Lancet Rheumatology
Anakinra - wikidoc
Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin–Resistant Kawasaki Disease - Koné‐Paut - 2021 - Arthritis & Rheumatology - Wiley Online Library
Anakinra Used in a Patient with Diffuse Large B-Cell Lymphoma and Steroid-Refractory Immune Effector Cell–Associated Neurotoxicity Syndrome: Case Report
Anakinra for Gout Flares: Is There a Role? | MedPage Today
